In 2019, the consistency of generic drugs was evaluated, and the acceptance numbers of these 6 pharmaceutical enterprises were all over 30

[industry trends of pharmaceutical network] in 2019, the consistency evaluation of generic drugs entered the intensive harvest period As of December 31, 2019, the total number of acceptance of consistency evaluation of listed generic drugs reached 1722 acceptance numbers, including 557 acceptance numbers of injection consistency evaluation In addition, the acceptance number of generic drug conformity assessment contractors reached 1038, an increase of 69.61% year on year The number of acceptance numbers passed was 237, with a year-on-year increase of 111.61% At present, a total of 473 enterprise conformity assessment varieties have been accepted, including 6 enterprises with acceptance number of more than 30, namely Qilu pharmaceutical, Kelun pharmaceutical, Ouyi pharmaceutical, Yangzijiang pharmaceutical, Hengrui pharmaceutical and humanwell pharmaceutical Compared with the original drugs, the six pharmaceutical companies have more than 30 acceptance numbers of conformity assessment of generic drugs, and 55 acceptance numbers of Qilu pharmaceuticals Compared with the original drugs, generic drugs have the advantages of consistent efficacy and low price To promote the R & D of generic drugs is to reduce the medical expenditure, improve the quality of life of the people and enhance the competitiveness of biological medicine in China In order to make more generic drugs benefit the people, Qilu pharmaceutical launched a number of consistency evaluation projects, competing against the clock to strengthen technical research, and finally made a large number of good drugs such as tegio capsule appear quickly Therefore, in addition to meeting the needs of patients, Qilu pharmaceutical has also become a big winner in the consistency evaluation At present, in addition to the acceptance number, the varieties that pass the consistency evaluation are also in the first place Kelun pharmaceutical: 37 acceptance numbers In recent years, Kelun pharmaceutical has been increasing investment in product research and development It is reported that since 2013, the R & D cost of Kelun pharmaceutical industry has exceeded 4.5 billion yuan Among them, the R & D cost in 2018 was RMB 1.114 billion, up 31.74% year on year; in the first half of 2019, the R & D cost reached RMB 666 million, up 32.51% year on year; in the third quarter of 2019, the R & D cost reached RMB 254 million Ouyi Pharmaceutical Co., Ltd of Sinopharm group: 34 acceptance numbers last month, Sinopharm group announced its first three quarters of 2019 results, with sales revenue of 16.761 billion yuan, up 27.5% year on year Among them, the sales revenue of innovative drugs reached 9.525 billion yuan, a year-on-year increase of 51.9%, accounting for more than 50% of the total revenue, and the sales revenue of anti-tumor drugs portfolio increased by 170.7% In addition, the R & D cost has reached 1.5 billion yuan At present, there are more than 300 research projects, mainly focusing on cardiovascular and cerebrovascular diseases, anti-tumor, diabetes, mental and neurological diseases and anti infection fields It is reported that Shiyao group will continue to actively promote the consistency evaluation of quality and efficacy of generic drugs The company plans to make full use of the opportunity brought by the consistency evaluation, actively strive for greater market share for products, and establish strategic cooperation with core distributors to expand and sink the terminal market to primary medical institutions Yangzijiang pharmaceutical industry: 34 acceptance numbers believe that the consistency evaluation of quality and efficacy of generic drugs is a process of great waves for pharmaceutical enterprises Challenges and opportunities coexist, requiring a large amount of technology, capital and time to overcome difficulties Under the guidance of the national policy of conformity evaluation of quality and efficacy of chemical generic drugs, Yangzijiang Pharmaceutical Co., Ltd quickly established a working group of conformity evaluation of generic drugs, which was responsible for the consistency research of all subsidiaries in the group, and implemented the work in six aspects of organization, standard, fund, time, task, inspection, etc., to ensure the steady progress of conformity evaluation At present, its results are also very significant Hengrui medicine: 34 acceptance numbers In fact, in Hengrui medicine's product system, more than 80% of its revenue comes from generics According to statistics, six generic drugs, including docetaxel, irinotecan, oxaliplatin, tegio, letrozole and capecitabine, contributed more than 6 billion sales revenue in 2018 However, compared with other chemical companies, Hengrui pharmaceutical now chooses the first generic drugs with great difficulty but strong competitiveness, such as fondaparinux sodium, which was launched in 2018, and temozolomide for injection, which was launched at the beginning of this year Therefore, once the products are launched, they will occupy the core position of import substitution This kind of R & D strategy also makes Hengrui pharmaceutical become the first enterprise with more varieties of generic drugs in China It is understood that in terms of input-output ratio, Hengrui has stopped general generic projects and will only make innovative drugs and high-end generic drugs with core value in the future Humanwell pharmaceutical: 30 acceptance numbers In fact, humanwell pharmaceutical has never been slack in the domestic generic pharmaceutical layout From January to February 2019, Yichang humanwell Corporation received a large number of consistency assessment applications, and 17 categories of 8 varieties were accepted in two months Some time ago, the relevant person in charge of humanwell pharmaceutical said at an activity that the product R & D of humanwell pharmaceutical is transforming from imitation based to combination of imitation and innovation The next stage is to speed up the progress of conformity evaluation of generic drugs, continue to speed up the product registration in Europe, America and other countries, and complete the upgrading of international quality system certification of all pharmaceutical production lines of the company Third, relying on the company's R & D base at home and abroad, the company has built innovation platforms in many fields, such as immunomodulatory anti-tumor, anti infective drugs, biopharmaceutical and new alternative drugs.